share_log

Deep Medicine Acquisition Corp. (NASDAQ:DMAQ) Sees Significant Increase in Short Interest

Deep Medicine Acquisition Corp. (NASDAQ:DMAQ) Sees Significant Increase in Short Interest

深度醫藥收購公司(納斯達克代碼:DMAQ)在空頭股數的持股大幅增加
kopsource ·  2022/10/05 08:52

Deep Medicine Acquisition Corp. (NASDAQ:DMAQ – Get Rating) was the target of a significant increase in short interest in the month of September. As of September 15th, there was short interest totalling 2,600 shares, an increase of 8.3% from the August 31st total of 2,400 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 22,500 shares, the short-interest ratio is presently 0.1 days.

深度醫藥收購公司(納斯達克代碼:dmaq-Get Rating)是空頭股數9月份大幅增長的目標。截至9月15日,空頭股數共有2,600股,比8月31日的2,400股增加了8.3%。該公司約0.0%的股份被賣空。以日均成交量22,500股計算,目前短息比率為0.1天。

Deep Medicine Acquisition Price Performance

深度醫療收購價格表現

Shares of DMAQ opened at $10.08 on Wednesday. Deep Medicine Acquisition has a 1 year low of $9.70 and a 1 year high of $10.99. The company's fifty day moving average is $10.05 and its two-hundred day moving average is $10.01.

週三,DMAQ的股價開盤報10.08美元。深度醫藥收購的一年低點為9.70美元,一年高位為10.99美元。該公司的50日移動均線切入位在10.05美元,200日移動均線切入位在10.01美元。

Get
到達
Deep Medicine Acquisition
深度醫學收購
alerts:
警報:

Institutional Trading of Deep Medicine Acquisition

深度醫藥收購的制度性交易

Hedge funds and other institutional investors have recently made changes to their positions in the company. Karpus Management Inc. acquired a new stake in Deep Medicine Acquisition in the fourth quarter valued at about $19,801,000. Saba Capital Management L.P. acquired a new stake in shares of Deep Medicine Acquisition in the 4th quarter valued at approximately $8,908,000. Beryl Capital Management LLC purchased a new stake in shares of Deep Medicine Acquisition in the fourth quarter valued at approximately $6,012,000. Oaktree Capital Management LP acquired a new position in Deep Medicine Acquisition during the fourth quarter worth $4,173,000. Finally, Hsbc Holdings PLC purchased a new position in Deep Medicine Acquisition in the first quarter worth $2,976,000. Hedge funds and other institutional investors own 89.62% of the company's stock.

對衝基金和其他機構投資者最近對他們在該公司的頭寸進行了調整。Karpus Management Inc.在第四季度收購了Deep Medicine收購的新股份,價值約為19,801,000美元。薩巴資本管理公司在第四季度收購了深度醫藥收購公司的新股份,價值約為8,908,000美元。貝麗爾資本管理有限責任公司在第四季度購買了深度醫藥收購公司的新股份,價值約為601.2萬美元。橡樹資本管理有限公司在第四季度收購了價值4,173,000美元的Deep Medicine收購的新頭寸。最後,滙豐控股在第一季度購買了深醫收購的新頭寸,價值297.6萬美元。對衝基金和其他機構投資者持有該公司89.62%的股票。

About Deep Medicine Acquisition

關於深度醫學的收購

(Get Rating)
(獲取評級)

Deep Medicine Acquisition Corp. does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It focuses on identifying businesses in the healthcare industry.

深度醫藥收購公司沒有重大業務。公司擬與一家或多家企業進行合併、資本換股、資產收購、股票購買、重組或類似的業務合併。它專注於識別醫療保健行業的企業。

See Also

另請參閲

  • Get a free copy of the StockNews.com research report on Deep Medicine Acquisition (DMAQ)
  • Don't Give Up on These Q3 Losers
  • The Anatomy of a Great Pension Plan
  • 3 Safe Earnings Plays for a Risk-Off Market
  • Tyson Foods Takes a Lickin' and Keeps on Tickin' Lower
  • Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
  • 免費獲取StockNews.com關於深度醫學收購的研究報告(DMAQ)
  • 不要放棄這些第三季度的失敗者
  • 一個偉大的養老金計劃的剖析
  • 避險市場的三大安全收益
  • 泰森食品股價下跌,繼續走低
  • 小盤股Catalyst Pharma是市場上價格表現最好的公司之一

Receive News & Ratings for Deep Medicine Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deep Medicine Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.

接受深度醫療收購日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收最新新聞和分析師對深度醫藥收購和相關公司評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論